Source: CureToday articles
Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer.
Recent Content
- CDC Clarifies That Kids May Receive COVID-19 Vaccine Through Shared Clinical Decision-Making
- Day 4: Top Takeaways from ASCO25
- Understanding the Side Effects of RLY-2608 in HR+, HER2– Breast Cancer
- FDA Approves mRNA-1283 COVID-19 Vaccine for Adults 65 and Older, Those With Underlying Conditions
- Q&A: High-fiber, plant-based diet may lower multiple myeloma risk
- Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in cUTIs Ends Early After Meeting Primary End Point
- New Jersey Society of Health-System Pharmacy Hosts 2nd Annual Pharmacy Leader and Pharmacy Technician Symposium
- Imlunestrant Alone or With Verzenios Improved PROs in Advanced Breast Cancer
- Informing Treatment Decisions Using a 14-Gene Assay in Early Non-Small Cell Lung Cancer
- ASCO 2025: Oncology Pathway Tools Show Consistent Usage Across Patient Groups